

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNITED GENE HIGH-TECH GROUP LIMITED

聯合基因科技集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

CLARIFICATION ANNOUNCEMENT

Reference is made to the circular dated 26 June 2014 (the “**Circular**”) of United Gene High-Tech Group Limited (the “**Company**”). Capitalized terms used herein shall have the same meanings as those defined in the Circular unless defined otherwise.

The Board wishes to clarify that due to inadvertent clerical errors, certain information in the Circular were mistakenly stated. The relevant errors and corrections made are as follows:

Certain figures in the table under the heading “Effects of the Acquisition on the Shareholding Structure of the Company” on page 22 were erroneous, the correct shareholding structure table should be as follows (with the revised numbers underlined and bold):

	As at the Latest Practicable Date		Immediately after Completion and assuming exercise in full of the conversion rights attaching to the Convertible Bonds at the conversion price of HK\$2.5 (subject to adjustments) per Conversion Share		Immediately after Completion and assuming exercise in full of the conversion rights attaching to the Convertible Bonds at the conversion price of HK\$2.5 (subject to adjustments) per Conversion Share and assuming the conversion of the Company's convertible bonds of HK\$133 million issued on 11 June 2013	
	No. of Shares (Note 4 & 6)	Approximate % of issued share capital of the Company (Note 4 & 6)	No. of Shares (Note 4)	Approximate % of issued share capital of the Company (Note 4)	No. of Shares (Note 6)	Approximate % of issued share capital of the Company (Note 6)
Substantial shareholder						
Dr. Mao Yumin	<u>56,640,000</u>	4.99%	<u>56,640,000</u>	3.98%	<u>56,640,000</u>	<u>3.94%</u>
United Gene Holdings Limited (Note 1)	67,500,000	5.94%	67,500,000	4.75%	<u>84,500,000</u>	<u>5.87%</u>
Best Champion Holdings Limited (Note 2)	61,650,000	5.43%	61,650,000	<u>4.34%</u>	<u>61,650,000</u>	<u>4.28%</u>
China United Gene Investment Holdings Limited (Note 3)	<u>178,201,350</u>	15.68%	<u>178,201,350</u>	12.53%	<u>178,201,350</u>	12.38%
Sub-total	363,991,350	32.04%	363,991,350	<u>25.60%</u>	<u>380,991,350</u>	<u>26.47%</u>
Chau Yiu Ting	121,500,000	10.69%	121,500,000	8.54%	<u>121,500,000</u>	<u>8.45%</u>
VMS Investment Group Limited	81,045,000	7.13%	81,045,000	5.70%	<u>81,045,000</u>	<u>5.63%</u>
Extrawell BVI (Note 5)	-	-	286,000,000	20.11%	<u>286,000,000</u>	<u>19.87%</u>
Sub-total	566,536,350	49.86%	852,536,350	59.95%	<u>869,536,350</u>	<u>60.42%</u>
Public Shareholders						
Other Shareholders	<u>569,656,674</u>	50.14%	<u>569,656,674</u>	40.05%	<u>569,656,674</u>	<u>39.58%</u>
Total	<u>1,136,193,024</u>	100.00%	<u>1,422,193,024</u>	100.00%	<u>1,439,193,024</u>	<u>100.00%</u>

Notes:

6. As at the Latest Practicable Date, conversion rights of the principal amount HK\$126.2 million attaching to the Company's convertible bonds of HK\$133 million issued on 11 June 2013 had been exercised.

Save and except for the said clarification, all the information in the Circular remains unchanged.

By Order of the Board
United Gene High-Tech Group Limited
Lee Nga Yan
Executive Director

Hong Kong, 10 July 2014

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).